Contents

Current Cancer Drug Targets, Volume 11 - Number 3

Editorial [Hot Topic: Targeting Tumor Uniquitin-Proteasome Pathway with New and Old Drugs (Guest Editor: Q. Ping Dou)]

, 11(3): 236 - 238

Q. Ping Dou


DOI: 10.2174/156800911794519789




Bortezomib as the First Proteasome Inhibitor Anticancer Drug: Current Status and Future Perspectives

, 11(3): 239 - 253

D. Chen, M. Frezza, S. Schmitt, J. Kanwar and Q. P. Dou


DOI: 10.2174/156800911794519752




Marizomib, a Proteasome Inhibitor for All Seasons: Preclinical Profile and a Framework for Clinical Trials

, 11(3): 254 - 284

B. C. Potts, M. X. Albitar, K. C. Anderson, S. Baritaki, C. Berkers, B. Bonavida, J. Chandra, D. Chauhan, J. C. Cusack, W. Fenical, I. M. Ghobrial, M. Groll, P. R. Jensen, K. S. Lam, G. K. Lloyd, W. McBride, D. J. McConkey, C. P. Miller, S. T.C. Neuteboom, Y. Oki, H. Ovaa, F. Pajonk, P. G. Richardson, A. M. Roccaro, C. M. Sloss, M. A. Spear, E. Valashi, A. Younes and M. A. Palladino


DOI: 10.2174/156800911794519716




Second Generation Proteasome Inhibitors: Carfilzomib and Immunoproteasome-Specific Inhibitors (IPSIs)

, 11(3): 285 - 295

D. J. Kuhn, R. Z. Orlowski and C. C. Bjorklund


DOI: 10.2174/156800911794519725




Green Tea Polyphenols as Proteasome Inhibitors: Implication in Chemoprevention

, 11(3): 296 - 306

H. Yang, K. Landis-Piwowar, T. H. Chan and Q. P. Dou


DOI: 10.2174/156800911794519743




Targeting Proteasomes with Naturally Occurring Compounds in Cancer Treatment

, 11(3): 307 - 324

V. Cecarini, M. Cuccioloni, M. Mozzicafreddo, L. Bonfili, M. Angeletti and A. M. Eleuteri


DOI: 10.2174/156800911794519815




Clioquinol – A Novel Copper-Dependent and Independent Proteasome Inhibitor

, 11(3): 325 - 331

A. D. Schimmer


DOI: 10.2174/156800911794519770




Targeting Malignancies with Disulfiram (Antabuse): Multidrug Resistance, Angiogenesis, and Proteasome

, 11(3): 332 - 337

B. Cvek


DOI: 10.2174/156800911794519806




Disulfiram, and Disulfiram Derivatives as Novel Potential Anticancer Drugs Targeting the Ubiquitin Proteasome System in Both Preclinical and Clinical Studies

, 11(3): 338 - 346

F. R. Kona, D. Buac and A. M. Burger


DOI: 10.2174/156800911794519798




SCF E3 Ubiquitin Ligases as Anticancer Targets

, 11(3): 347 - 356

L. Jia and Y. Sun


DOI: 10.2174/156800911794519734




Autophagy: Molecular Mechanisms and their Implications for Anticancer Therapies

, 11(3): 357 - 379

S. Meschini, M. Condello, P. Lista and G. Arancia


DOI: 10.2174/156800911794519707




Peptidyl Prolyl Isomerase, Pin1 is a Potential Target for Enhancing the Therapeutic Efficacy of Etoposide

, 11(3): 380 - 392

R. Mathur, S. Chandna, P. N. Kapoor and B. S. Dwarakanath


DOI: 10.2174/156800911794519761




Webmaster Contact: info@benthamscience.org
Copyright © 2018 Bentham Science